THOROFARE, NJ--(Marketwired - Mar 28, 2017) - Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers Bio"), a developer of rapid health information technologies, has received an initial order for the Company's rapid cholesterol self-test from First Check Diagnostics, LLC ("First Check"), the exclusive distributor for this product in the United States, for sale under their popular "First Check" brand.

 

First Check products are sold through major retailers including, CVS, Rite Aid, Target, Kmart, Meijer, Giant Eagle, Stop & Shop, Giant and ShopKo.

 

Akers Bio's Tri-Cholesterol "Check" test is the only combined rapid test which provides an estimate of a person's Total cholesterol as well as their High Density Lipoprotein ("HDL") cholesterol levels - their 'good cholesterol'; thereby providing an estimate of a person's Low Density Lipoprotein ("LDL") levels - their 'bad cholesterol'. These features are essential to accurately differentiating between a person's 'good' and 'bad' cholesterol thereby making it a truly effective screening test for high cholesterol.

2017-02-15 08:31 ET - News Release

 

Added 5.2 million net new customers and achieved double digit Gross Profit growth in North America for 2016

 

Fourth quarter revenue of $934.9 million, $3.1 billion for the full year

Fourth quarter gross billings of $1.7 billion, $6.1 billion for the full year

Fourth quarter net loss of $50.2 million, $183.3 million for the full year

Fourth quarter Adjusted EBITDA of $80.6 million, $178.1 million for the full year

Fourth quarter loss per share of $0.09; non-GAAP earnings per share of $0.07

SOLANA BEACH, Calif., Feb. 15, 2017  -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, today announced that it has received a letter from FDA exempting its late stage product, Gimoti™ from a Human Factors (HF) Validation study requirement prior to submission of a New Drug Application (NDA).

 

In February 2016, FDA published new guidance entitled “Applying Human Factors and Usability Engineering to Medical Devices”, which requires drug products classified as a drug/device combination, such as Gimoti, undergo evaluation that may require an HF Validation study as described in FDA’s Guidance. 

ROUYN-NORANDA, QUEBEC--  Jan. 18, 2017) -GLOBEX MINING ENTERPRISES INC. (TSX:GMX)(FRANKFURT:G1M)(STUTTGART:G1M)(BERLIN:G1M)(MUNICH:G1M)(XETRA:G1M)(OTCQX:GLBXF) is please to inform shareholders of the results of a drill hole on our Francoeur Gold Mine Property, 25 km west of Rouyn-Noranda, Quebec.

 

Drill hole FS-16-35 intersected 4.64 gpt Au over 8 m from 99 to 107 m including 8.01 gpt Au over 4 m from 100 to 104 m (0.14 oz/t Au over 26.25 feet between 324.8 feet and 351.1 feet including 0.23 oz/t Au over 13.12 feet from 328.1 to 341.2 feet). The true width is approximated 55% of the intersection width. The gold intersection occurs at a vertical depth of approximately 90 m (295 ft) below surface in altered and fractured diorite and mafic volcanics with carbonate/silica/hematite alteration.